P/B
—
Veracyte
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
$4.2B
Market Cap • 11/4/2026
2006
(20 years)
Founded
2013
(13 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
7,3
P/EBITDA
34,9
P/OCF
24,3
P/FCF
26,1
P/E
33,9
BVPS
—
EPS
1,5
Market Cap
Market Cap
4,2B
EV
3,9B
EV/Revenue
6,7
EV/EBITDA
32,2
EV/EBIT
39,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0,1%
Total Yield
0,1%
Payout
0%
Profitability
Gross Margin
72%
EBITDA Margin
20,8%
EBIT Margin
17,1%
Net Margin
21,8%
D&A/EBITDA
1,7%
R&D/Revenue
18,8%
Capex/Revenue
2,1%
Capex/D&A
55,4%
Capex/OCF
6,9%
SBC/OCF
29,7%
% PPE
3,8%
% Goodwill
54,4%
ROE
20,2%
ROIC
9,7%
Growth
CAGR Revenue 5Y
25,5%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
5,6
Quick Ratio
5,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!